TABLE 2 ] .
Comparison of Group 1 Patients Who Were Not Diagnosed With MAA Lung Disease vs Group 2 Patients Who Were Diagnosed With MAA Lung Disease
| Characteristics | Group 1 | Group 2 | P Value (95% CI) |
| Patients, No. | 32 | 21 | … |
| Total AFB cultures obtained | 39.3 ± 19.4 | 41.7 ± 19.7 | 0.7 (95% CI, −13.4 to 8.6) |
| Total AFB cultures positive for MAA | 1.2 ± 0.4 (range, 1-3) | 15.0 ± 11.1 | < .0001 (95% CI, −17.7 to −9.9) |
| Single, positive MAA AFB culture | 25/32 (78) | 0/21 | < .0001 |
| ATS/IDSA microbiologic diagnostic criteria met | 7/32 (22) | 21/21 (100) | < .0001 |
| All three ATS/IDSA diagnostic criteria met | 0/32 (0) | 21/21 (100) | < .0001 |
| New or enlarging cavitary lesion associated with MAA isolationa | 0/32 (0) | 8/21 (38) | < .001 |
| Isolation of other waterborne NTMb | 13/32 (41) | 5/21 (24) | .2 |
| Isolation of bronchiectasis-related bacteriac | 28/32 (86) | 17/21 (81) | .7 |
| Mean duration of follow-up after successful MAC therapy, mean±SD, mo | 45.6 ± 36.1 | 48.3 ± 28.7 | .8 (95% CI, −21.5 to 16.1) |
| Patients treated for MAA | 0/32 | 11/21 (52) | < .0001 |
| Treated concomitantly for MAC and MAA | … | 5/11 (45) | … |
| Successful treatment of MAC and MAA | … | 3/5 (60) | … |
| Successful treatment of MAA after completion of MAC therapy | … | 3/6 (50) | … |
Data given as No./total (%) unless otherwise indicated. AFB = acid-fast bacilli; ATS = American Thoracic Society, IDSA = Infectious Diseases Society of America; NTM = nontuberculous mycobacteria. See Table 1 legend for expansion of other abbreviations.
a
≥ 2.0-cm diameter.
b
Mycobacterium gordonae, Mycobacterium terrae, and so forth.
c
Pseudomonas species, Stenotrophamonas species, and so forth.